Aspects of Modern Drug Use

  • Ronald D. Mann
Chapter

Abstract

Most people would now acknowledge that humane social attitudes and an environment produced by attention to the public health, are preventive of disease. The conditions of inner city life for many people, the numbers of persons unemployed, the somewhat feudal exposure of the employee to the employer, and other such factors, suggest that the accomplishment of the body politic has been limited. But compared with the previous century it has been real.

Keywords

British Medical Journal Modern Drug Product Licence Yellow Card License Authority 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 2325.
    BPC (1934). As ref. 120 but p. 164Google Scholar
  2. 2326.
    Ministry of Health, Reports on public health and medical subjects No. 112. Deformities caused by thalidomide. London, HMSO, 1964, p. iiiGoogle Scholar
  3. 2327.
    Ministry of Health (1964). As ref. 2326 but Plate 4Google Scholar
  4. 2328.
    Kunz, W., Keller, H. and Mückter, H. Arzneim.-Forsch., 1956, 6, 426. See Jung, Herman. Klinische Erfahrungen mit einem neuen Sedativum. Arzneim.-Forsch., 1956, 6, 430–432Google Scholar
  5. 2329.
    Murdoch, J. McC. and Campbell, G. D. Antithyroid activity of N-phthalyl glutamic acid imide (K17). Br. Med. J., 1958, 1, 84–85PubMedCrossRefGoogle Scholar
  6. 2330.
    Teff, Harvey and Munro, Colin, R. Thalidomide, the legal aftermath. Farnborough, Saxon House, 1976Google Scholar
  7. 2331.
    Sjöström, Henning and Nilsson, Robert. Thalidomide and the power of the drug companies. Harmondsworth, Penguin, 1972, p. 53Google Scholar
  8. 2332.
    Sjöström and Nilsson (1972). As ref. 2331 but p. 56Google Scholar
  9. 2333.
    Teff and Munro (1976). As ref. 2330 but p. xiiGoogle Scholar
  10. 2334.
    Florence, A. Leslie. Is thalidomide to blame? Br. Med. J., 1960, 2, 1954CrossRefGoogle Scholar
  11. 2335.
    Burley, Denis. Is thalidomide to blame? Br. Med. J., 1961, 1, 130CrossRefGoogle Scholar
  12. 2336.
    Kuenssberg, E.V. et al. Is thalidomide to blame? Br. Med. J., 1961, 1, 291CrossRefGoogle Scholar
  13. 2337.
    Shafar, J. Is thalidomide to blame? Br. Med. J., 1961, 1, 829CrossRefGoogle Scholar
  14. 2338.
    Frenkel, H. Contergan-Nebenwirkungen. Die Med. Welt, 1961, 1(18), 970–975Google Scholar
  15. 2339.
    Schied, W. von. et al. Polyneuritische Syndrome nach längerer Thalidomid-Medikation. Dtsch. Med. Wschr., 1961, 86, 938–941CrossRefGoogle Scholar
  16. 2340.
    Raffauf, Hans Joachim von. Bewirkt Thalidomid (Contergan) keine Schäden? Dtsch. Med. Wschr., 1961, 86, 935–938PubMedCrossRefGoogle Scholar
  17. 2341.
    Anonymous. Purpura associated with thalidomide. Br. Med. J., 1961, 2, 125CrossRefGoogle Scholar
  18. 2342.
    Longstaff, J.H. Purpura associated with thalidomide. Br. Med. J., 1961, 2, 660Google Scholar
  19. 2343.
    Fullerton, Pamela M. and Kremer, Michael. Neuropathy after intake of thalidomide (Distaval). Br. Med. J., 1961, 2, 855–858PubMedCrossRefGoogle Scholar
  20. 2344.
    Anonymous. Thalidomide neuropathy. Br. Med. J., 1961, 2, 876–877CrossRefGoogle Scholar
  21. 2345.
    Heathfield, K.W.G. Neuropathy after thalidomide (‘Distaval’). Br. Med. J., 1961, 2, 1084CrossRefGoogle Scholar
  22. 2346.
    Powell-Tuck, G. A. Neuropathy after thalidomide (‘Distaval’). Br. Med. J., 1961, 2, 1151CrossRefGoogle Scholar
  23. 2347.
    Stevenson, J. S. K. Neuropathy after thalidomide (‘Distaval’). Br. Med. J., 1961, 2, 1223CrossRefGoogle Scholar
  24. 2348.
    Jewesbury, Eric C.O. Neuropathy after thalidomide (‘Distaval’). Br. Med. J., 1961, 2, 1286CrossRefGoogle Scholar
  25. 2349.
    Magrath, D. Neuropathy after thalidomide (‘Distaval’). Br. Med. J., 1961, 2, 1359CrossRefGoogle Scholar
  26. 2350.
    Hayman, D.J. Neuropathy after thalidomide (‘Distaval’). Br. Med. J., 1961, 2, 1435CrossRefGoogle Scholar
  27. 2351.
    Kremer, Michael and Fullerton, Pamela, M. Neuropathy after thalidomide (‘Distaval’). Br. Med. J., 1961, 2, 1498. (See also p. 1499)CrossRefGoogle Scholar
  28. 2352.
    McBride, W.G. Thalidomide and congenital abnormalities. Lancet, 1961, 4, 1358CrossRefGoogle Scholar
  29. 2353.
    McBride, W.G. Congenital abnormalities and thalidomide. Med. J. Aust., 1961, (Dec. 23), 1030Google Scholar
  30. 2354.
    Lenz, W. Thalidomide and congenital abnormalities. Lancet, 1962, 1, 45CrossRefGoogle Scholar
  31. 2355.
    Pfeiffer, R.A. and Kosenow, W. Thalidomide and congenital abnormalities. Lancet, 1962, 1, 45–46Google Scholar
  32. 2356.
    Somers, G.F. Thalidomide and congenital abnormalities. Lancet, 1962, 2, 912–913CrossRefGoogle Scholar
  33. 2357.
    Knightley, Phillip et al. Suffer the children: the story of thalidomide. London, Andre Deutsch, 1979Google Scholar
  34. 2358.
    Skre, Håvard. Thalidomide embryopathy and neuropathy, some correlations with embryology and teratology. Bergen, Norwegian Univ. Press, 1963Google Scholar
  35. 2359.
    McCredie, Janet. Thalidomide and congenital Charcot’s Joints. Lancet, 1973, 4, 1058–1061CrossRefGoogle Scholar
  36. 2360.
    Jurand, A. Early changes in limb buds of chick embryos after thalidomide treatment.J. Embryol. Exp. Morph., 1966, 16(2), 289–300PubMedGoogle Scholar
  37. 2361.
    Poswillo, David. Hemorrhage in development of the face. Brith Defects: Original Article Series, 1975, XI(7), 61–81Google Scholar
  38. 2362.
    Williams, R. Teewyn. Thalidomide, a study of biochemical teratology. Arch. Environ. Health, 1968, 16, 493–502PubMedGoogle Scholar
  39. 2363.
    Kohler, F. et al. Embryotoxicitat und Teratogenitat von Derivaten des 1,3-Indandion. Arch. Toxicol. (Berl), 1975, 33(3), 191–197CrossRefGoogle Scholar
  40. 2364.
    Gordon, G.B. et al. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite, Proc. Natl. Acad. Sci. USA, 1981, 78(4), 2545–2548PubMedCrossRefGoogle Scholar
  41. 2365.
    McBride, W.G. Fetal nerve cell degeneration produced by thalidomide in rabbits. Teratology, 1974, 10, 283–292PubMedCrossRefGoogle Scholar
  42. 2366.
    McBride, W.G. Studies of the etiology of thalidomide dysmorphogenesis. Teratology, 1976, 14, 71–87PubMedCrossRefGoogle Scholar
  43. 2367.
    Schardein, James L. Drugs as teratogens. Cleveland, CRC Press, 1976Google Scholar
  44. 2368.
    Gregg, N. McAlister. Congenital cataract following german measles in the mother. Trans. Ophthalmol. Soc. Aust., 1941, 3, 35–46Google Scholar
  45. 2369.
    Schardein, James L. (1976). As ref. 2367 but p. 5Google Scholar
  46. 2370.
    Schardein, James L. (1976). As ref. 2367 but p. 6Google Scholar
  47. 2371.
    Robertson, Richard T. et al. Aspirin: teratogenic evaluation in the dog. Teratology, 1979, 20, 313–320PubMedCrossRefGoogle Scholar
  48. 2372.
    Layton, William M. An analysis of teratogenic testing procedures. In Janerich, D.T., Skalko, R.G. and Porter, I.H. (eds.) Congenital defects, New York, Academic Press, 1974, pp. 205–217Google Scholar
  49. 2373.
    Secret remedies, what they cost and what they contain. London, British Medical Association, 1909Google Scholar
  50. 2374.
    More secret remedies, what they cost and what they contain. London, British Medical Association, 1912Google Scholar
  51. 2375.
    Report from the Select Committee on patent medicines, together with the proceedings of the Committee, minutes of evidence, and appendices. London, HMSO, 1914Google Scholar
  52. 2376.
    Penn, Raymond G. The state control of medicines: the first 3000 years. Br. J. Clin. Pharmac., 1979, 8, 293–305Google Scholar
  53. 2377.
    Hartley, Sir Frank. The Medicines Act and the physician. In Harcus, A. W. (ed.) Risk and regulation in medicine - the fettered physician. London, Association of Medical Advisors in the Pharmaceutical Industry, 1980, pp. 9–23Google Scholar
  54. 2378.
    Committee on Safety of Drugs. Report of the Committee on Safety of Drugs for the year ended December 31st, 1964 … London, HMSO, 1965Google Scholar
  55. 2379.
    Committee on Safety of Drugs. Report for the year ended December 31st, 1965 … London, HMSO, 1966Google Scholar
  56. 2380.
    Committee on Safety of Drugs. Report for the year ended December 31st, 1966 … London, HMSO, 1967Google Scholar
  57. 2381.
    Committee on Safety of Drugs. Report for the year ended December 31st, 1967 … London, HMSO, 1968Google Scholar
  58. 2382.
    Committee on Safety of Drugs. Report for the year ended December 31st, 1968 … London, HMSO, 1969Google Scholar
  59. 2383.
    Committee on Safety of Drugs. Report for 1969 and 1970. London, HMSO, 1971Google Scholar
  60. 2384.
    Inman, W.H.W. et al. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br. Med. J., 1970, 2, 203–209PubMedCrossRefGoogle Scholar
  61. 2385.
    Inman, W. H. W. and Adelstein, A. M. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols.Lancet, 1969, 2, 279–285PubMedCrossRefGoogle Scholar
  62. 2386.
    Committee on Safety of Medicines. Report for the year ended 31st December, 1971. London, HMSO, 1972Google Scholar
  63. 2387.
    Department of Health & Social Security. Medicines Act leaflet. A guide to the licensing system (MAL 1). London, DHSS, Medicines Division, 1976Google Scholar
  64. 2388.
    The Medicines (Data Sheet) Regulations 1972. S.I. 1972 No. 2076. London, HMSO, 1973Google Scholar
  65. 2389.
    Inman, William H.W. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br. Med. 1977, 1, 1500–1505CrossRefGoogle Scholar
  66. 2390.
    Quantock, D.C. The effect of regulation on international drug development. In Harcus, A. W. (1980). As ref. 2377 but pp. 85–94Google Scholar
  67. 2391.
    Wardell, W.M. What is the proper role of a drug regulatory agency? In Harcus, A.W. (1980). As ref. 2377 but pp. 95–113Google Scholar
  68. 2392.
    v. Scrip No. 815, 1983, p. 1Google Scholar
  69. 2393.
    British National Formulary, Number 4 (1982). London,British Medical Association and The Pharmaceutical Society of Great Britain, 1982, p. 110Google Scholar
  70. 2394.
    The Medicines (Exemption from Licences) (Clinical Trials) Order 1981. S.I. 1981 No. 164. London, HMSO, 1981Google Scholar
  71. 2395.
    Griffin, John P. Post-marketing surveillance. In Wardell, W. M. and Velo, G. (eds.) Drug development, regulatory assessment, and postmarketing surveillance. New York, Plenum, 1981, pp. 241–249Google Scholar
  72. 2396.
    D’Arcy, Patrick Francis and Griffin, John Parry. Iatrogenic diseases. (2nd edn.), Oxford, Univ. Press, 1979. (1st edn., 1972)Google Scholar
  73. 2397.
    D’Arcy, Patrick F. and Griffin, John P. (1979). As ref. 2396 but p. 39Google Scholar
  74. 2398.
    D’Arcy, Patrick F. and Griffin, John P. (1981). As ref. 2396 but ‘Update 1981’, p. 10Google Scholar
  75. 2399.
    D’Arcy, Patrick F. and Griffin, John P. (1981). As ref. 2398, p. 10Google Scholar
  76. 2400.
    D’Arcy, Patrick F. and Griffin, John P. (1981). As ref. 2398 but p. 11Google Scholar
  77. 2401.
    Melmon, Kenneth L. Preventable drug reactions – causes and cures. New Engl. J. Med., 1971, 284, 1361–1368PubMedCrossRefGoogle Scholar
  78. 2402.
    Girdwood, R.H. Death after taking medicaments. Br. Med. J., 1974, 1, 501–504PubMedCrossRefGoogle Scholar
  79. 2403.
    Caranasos, George J. et al. Drug-associated deaths of medical inpatients. Arch. Intern. Med., 1976, 136, 872–875PubMedCrossRefGoogle Scholar
  80. 2404.
    Porter, Jane and Jick, Hershel. Drug-related deaths among medical inpatients. J. Am. Med. Assoc., 1977, 237, 879–881CrossRefGoogle Scholar
  81. 2405.
    Anonymous. Deaths due to drug treatment. (Editorial), Brit. Med. J., 1977, 1, 1492–1493CrossRefGoogle Scholar
  82. 2406.
    Inman, William, H. W. In Inman, W. H. W. (ed.) Monitoring for drug safety. Lancaster, MTP Press, 1980, p. 15Google Scholar
  83. 2407.
    Cuthbert, M.F., Griffin, J. P. and Inman, W. The United Kingdom. In William M. Wardell (ed.) Controlling the use of therapeutic drugs, an international comparison. Washington, American Enterprise Institute, 1978, p. 133Google Scholar
  84. 2408.
    Inman, William H.W. Standpoint of the regulating agency in the U.K. In A.F. De Schaepdryver and others (eds.) The scientific basis of official regulation of drug research and development. Ghent, Hey mans Foundation, 1978, p. 137Google Scholar
  85. 2409.
    Dollery, Colin T. and Rawlins, Michael D. Monitoring adverse reactions to drugs.Br. Med. J., 1977, 1, 96–97PubMedCrossRefGoogle Scholar
  86. 2410.
    Schimmel, Elihu M. The hazards of hospitalization. Ann. Intern. Med., 1964, 60, 100–110PubMedGoogle Scholar
  87. 2411.
    MacDonald, Murdo G. and Mackay, Bruce R. Adverse drug reactions, experience of Mary Fletcher Hospital during 1962. J. Am. Med. Assoc., 1964, 190, 1071–1074Google Scholar
  88. 2412.
    Seidl, L. G. et al. Studies on the epidemiology of adverse drug reactions. III. Reactions in patients on a General Medical Service. Bull. Johns Hopk. Hosp., 1966, 119, 299–315Google Scholar
  89. 2413.
    Reidenberg, Marcus M. Registry of adverse drug reactions. Report of the Drug Reaction Registry Subcommittee of the Greater Philadelphia Committee for Medical-Pharmaceutical Sciences. J. Am. Med. Assoc., 1968, 203, 31–34CrossRefGoogle Scholar
  90. 2414.
    Smith, Jay W. et al. Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility. Ann. Intern. Med., 1966, 65, 629–640PubMedGoogle Scholar
  91. 2415.
    Ogilvie, R.I. and Ruedy, J. Adverse drug reactions during hospitalization. Can. Med. Assoc. J., 1967, 97 1450–1457PubMedGoogle Scholar
  92. 2416.
    Hoddinott, B.C. et al. Drug reactions and errors in administration on a medical ward. Can. Med. Assoc. J., 1967, 97, 1001–1006PubMedGoogle Scholar
  93. 2417.
    Borda, I.T. et al. (Boston Collaborative Drug Surveillance Program). Assessment of adverse reactions within a drug surveillance program. J. Am. Med. Assoc., 1968, 205, 645–647CrossRefGoogle Scholar
  94. 2418.
    Hurwitz, Natalie and Wade, O.L. Intensive hospital monitoring of adverse reactions to drugs. Br. Med. J., 1969, 1, 531–536PubMedCrossRefGoogle Scholar
  95. 2419.
    Hurwitz, Natalie. Admissions to hospital due to drugs. Br. Med. J., 1969, 1, 539–540PubMedCrossRefGoogle Scholar
  96. 2420.
    Gardner, Pierce and Watson, L. Jeannine. Adverse drug reactions: a pharmacist-based monitoring system. Clin. Pharmacol. Ther., 1970, 11, 802–807PubMedGoogle Scholar
  97. 2421.
    Wang, R.I.H. and Terry, L.C. Adverse drug reactions in a Veterans Administration Hospital. J. Clin. Pharmacol, 1971, 11, 14–18CrossRefGoogle Scholar
  98. 2422.
    Boston Collaborative Drug Surveillance Program. Adverse drug interactions. J. Am. Med. Assoc., 1972, 220, 1238–1239CrossRefGoogle Scholar
  99. 2423.
    Miller, R. R. Drug surveillance utilizing epidemiologic methods: a report from the Boston Collaborative Drug Surveillance Program. Am. J. Hosp. Pharm., 1973, 30, 584–592PubMedGoogle Scholar
  100. 2424.
    Mulroy, R. Iatrogenic disease in general practice: its incidence and effects. Br. Med. J., 1973, 2, 407–410PubMedCrossRefGoogle Scholar
  101. 2425.
    Jick, Hershel. Drugs – remarkably nontoxic. New Engl. J. Med., 1974, 291, 824–828PubMedCrossRefGoogle Scholar
  102. 2426.
    Caranasos, G.J. et al. Drug-induced illness leading to hospitalization. J. Am. Med. Assoc., 1974, 228, 713–717CrossRefGoogle Scholar
  103. 2427.
    McKenney, J.M. and Harrison, W.L. Drug-related hospital admissions.Am. J. Hosp. Pharm., 1976, 33, 792–795PubMedGoogle Scholar
  104. 2428.
    McKenzie, M. W. et al. Adverse drug reactions leading to hospitalization in children. J. Pediatr., 1976, 89, 487–490PubMedCrossRefGoogle Scholar
  105. 2429.
    Levy, M. et al. Drug utilization and adverse drug reactions in medical patients. Comparison of two periods, 1969–72 and 1973–76. Israel J. Med. Sci., 1977, 13, 1065–72PubMedGoogle Scholar
  106. 2430.
    Martys, Cedrick R. Adverse reactions to drugs in general practice. Br. Med. J., 1979, 2, 1194–1197PubMedCrossRefGoogle Scholar
  107. 2431.
    Lawson, D.H. and Henry, D.A. Monitored adverse reactions to new drugs: ‘restricted release’ or ‘monitored release’? Bri. Med. J., 1977, 1, 691–692CrossRefGoogle Scholar
  108. 2432.
    Wilson, A.B. Post-marketing surveillance of adverse reactions to new medicines. Br. Med. J., 1977, 2, 1001–1003PubMedCrossRefGoogle Scholar
  109. 2433.
    Nicholls, J.T. The practolol syndrome – a retrospective analysis. In Post-marketing surveillance of adverse reactions to new medicines, report of a meeting held on 7 December 1977 under the chairmanship of Sir Richard Doll. MedicoPharmaceutical Forum, publication No. 7, 1977, pp. 4–11Google Scholar
  110. 2434.
    Anonymous. Journal of the Royal College of Physicians, 1977, 11, cited by Br. Med. J., 1977, 1, 861–862Google Scholar
  111. 2435.
    Drug monitoring; proceedings of an International Workshop held in Honolulu from 24 to 28 January, 1977 and sponsored by Ciba-Geigy. eds. Gross, F.H. and Inman, W.H.W. London, Academic Press, 1977Google Scholar
  112. 2436.
    Crawford, J.M. (1977). As ref. 2435 but pp. 55–58Google Scholar
  113. 2437.
    Inman, W. H. W. (1977). As ref. 2435 but pp. 65–78Google Scholar
  114. 2438.
    Anonymous (1977). As ref. 2435 but p. 308Google Scholar
  115. 2439.
    Anonymous. New strategies for drug monitoring. Br. Med. J. 1977, 1, 861–862CrossRefGoogle Scholar
  116. 2440.
    Skegg, D. C. G. (1977) As ref. 2435 but p. 59Google Scholar
  117. 2441.
    Anonymous. New proposals on surveillance of drugs. Br. Med. J., 1978, 1, 588Google Scholar
  118. 2442.
    Anonymous. Postmarketing surveillance of drugs.Br. Med. J., 1979, 1, 1229CrossRefGoogle Scholar
  119. 2443.
    Skegg, D. C. G. and Doll, Sir Richard. The case for recording events in clinical trials. Br. Med. J., 2, 1523–1524Google Scholar
  120. 2444.
    Shapiro, Samuel and Slone, Dennis. Post-marketing assessment of drugs. In ref. 2433 (1977) but pp. 19–26Google Scholar
  121. 2445.
    Jones, Judith K. (1981). As ref. 2395 but pp. 233–240Google Scholar
  122. 2446.
    Jick, Hershel. The discovery of drug-induced illness. New Engl. J. Med., 1977, 296, 481–485PubMedCrossRefGoogle Scholar
  123. 2447.
    Wardell, William M. and Lasagna, Louis. Regulation and drug development. Washington, DC, American Enterprise Institute for Public Policy Research, 1975, p. 105Google Scholar
  124. 2448.
    Bloch, Hubert. Toward better systems of drug regulation. In Regulating new drugs, ed. Landau, Richard L. Chicago, Univ. of Chicago Center for Policy Study, 1973, p. 263Google Scholar
  125. 2449.
    Snell, Eric S. Regulatory authorisation of clinical trials. Br. J. Clin. Pharmac., 1983, 15, 625–627Google Scholar
  126. 2450.
    Wardell, William M. (1981). As ref. 2395 but pp. 3–4Google Scholar
  127. 2451.
    Dukes, M.N.G. and Lunde, I. (1980). As ref. 2377 but pp. 180–181Google Scholar
  128. 2452.
    Diggle, Geoffrey E. and Griffin, John P. Licensing times in granting marketing authorizations for medicines – a comparison between the U.K. and U.S.A.Pharmacy Int., 1982, 3, 230–236Google Scholar
  129. 2453.
    Griffin, John P. and Diggle, Geoffrey E. A survey of products licensed in the United Kingdom from 1971–1981. Br. J. Clin. Pharmac., 1981, 12, 453–463Google Scholar
  130. 2454.
    Annual reports for 1980 of Medicines Commission, Committee on Safety of Medicines, etc. London, HMSO, 1981Google Scholar
  131. 2455.
    Annual reports for 1981 of Medicines Commission, Committee on Safety of Medicines, etc. London, HMSO, 1982Google Scholar
  132. 2456.
    Griffin, John P. and D’Arcy, P.F. Adverse reactions to drugs – the information lag. In Side effects of drugs annual, ed. Dukes, M.N.G. Amsterdam, Excerpta Medica, pp. xv-xxivGoogle Scholar
  133. 2457.
    Twomey, C. E. J. and Griffin, John P. The information lag - has it improved? Pharmacy Int., 1983 (March), 57–61Google Scholar
  134. 2458.
    Current Problems, Number 1. Committee on Safety of Medicines. London, HMSO, 1975 (Sept.). No. 2, August 1976; No. 3, February 1978; No. 4, April 1979; No. 5, February 1981; No. 6, July 1981; No. 7, December 1981; No. 8, October 1982; No. 9, January 1983; No. 10, April, 1983; No. 11, August 1983; No. 12, October 1983Google Scholar
  135. 2459.
    Venning, Geoffrey R. Identification of adverse reactions to new drugs. I. What have been the important adverse reactions since thalidomide? Br. Med. J., 1983, 286, 199–202. (Then parts:) II, ibid, pp. 289–292; II (cont.) ibid, pp. 365–368; III ibid, pp. 458–460; IV ibid, pp. 544–547CrossRefGoogle Scholar
  136. 2460.
    Nestor, J.O. Results of the failure to perform adequate preclinical studies before administering new drugs to humans. S. A. Med. J. (Suppl. S.A. J. Lab. Clin. Med.), 1975, 49, 287–290Google Scholar
  137. 2461.
    Dukes, M.N.G. The paradox of clioquinol and SMON. In D’Arcy and Griffin. As ref. 2396 but Update 1981, pp. 105–113Google Scholar
  138. 2462.
    Campbell, P.G. Drug-induced disorders of central nervous function. In D’Arcy and Griffin. As ref. 2396 but pp. 114–136Google Scholar
  139. 2463.
    Committee on Safety of Medicines. CSM/ AR/ 18C, May 1973Google Scholar
  140. 2464.
    Felix, R.H. et al. Cutaneous and ocular reactions to practolol. Br. Med. J., 1974, 4, 321–324PubMedCrossRefGoogle Scholar
  141. 2465.
    Wright, Peter. Untoward effects associated with practolol administration: oculo-mucocutaneous syndrome. Br. Med. J., 1975, 1, 595–598PubMedCrossRefGoogle Scholar
  142. 2466.
    Anonymous. Side effects of practolol.Br. Med. J., 1975, 1, 577–578Google Scholar
  143. 2467.
    Anonymous. After practolol. Br. Med. J., 1977, 2, 1561–1562CrossRefGoogle Scholar
  144. 2468.
    Department of Health and Social Security. On the state of the public health. The Annual Report of the Chief Medical Officer… for the year 1982. London, HMSO, pp. 122–123Google Scholar
  145. 2469.
    Lawton, The Right Hon. Lord Justice. Legal aspects of iatrogenic disorders: discussion paper. J. R. Soc. Med., 1983, 76, 289–291PubMedGoogle Scholar
  146. 2470.
    Weber, J.C.P. Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs. In Side-effects of anti-inflammatory analgesic drugs, eds. Rainsford, K.D. and Velo, G. New York, Raven Press, 1984, Vol.’6, pp. 1–7Google Scholar
  147. 2471.
    Cuthbert, M. F. Adverse reactions to anti-rheumatic drugs: some correlations with animal toxicity studies. In Current approaches in toxicology, ed. Ballantyne, Bryan. Bristol, John Wright, 1977, pp. 279–28Google Scholar

Copyright information

© Ronald D. Mann 1984

Authors and Affiliations

  • Ronald D. Mann

There are no affiliations available

Personalised recommendations